Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133

Phase 1RBD3133Positive

AI Analysis

Summary

Ribo announced successful submission of a Phase 1 Clinical Trial Application in the EU for RBD3133, an INHBE-targeting siRNA therapeutic candidate. The submission represents a regulatory milestone for the company's RNA interference pipeline.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Clinical Trial Application submitted to EU

Importance:5/10

Sentiment:

0.60

Phase 1siRNAEU Clinical TrialChina biotechRegulatory submission

Related Companies

$06938.HK

Read the original article

Published by PR Newswire Biotech on October 8, 2026 2:57 AM

Read Original